Breast cancer mutation in GATA3 zinc finger 1 induces conformational changes leading to the closer binding of ZnFn2 with a wrapping architecture

References

• Adomas, A. B., Grimm, S. A., Malone, C., Takaku, M., Sims, J. K., & Wade, P. A. (2014). Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. BMC Cancer, 14(1), 278. doi:10.1186/1471-2407-14-278
   PubMedGoogle Scholar
• Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015). Precision medicine for metastatic breast cancer-limitations and solutions. Nature Reviews Clinical Oncology, 12, 693–704. doi: 10.1038/nrclinonc.2015.123
   PubMed Web of Science ®Google Scholar
• Berman, H., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P. (2000). Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. doi: 10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018). Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 18, 89–102. doi: 10.1038/nrc.2017.109
   PubMed Web of Science ®Google Scholar
• Chen, Y., Bates, D. L., Dey, R., Chen, P.-H., Machado, A. C. D., Laird-Offringa, I. A., … Chen, L. (2012). DNA binding by GATA transcription factor suggests mechanisms of DNA looping and long-range gene regulation. Cell Reports, 2(5), 1197–1206. doi: 10.1016/j.celrep.2012.10.012
   PubMed Web of Science ®Google Scholar
• Cohen, H., Ben-Hamo, R., Gidoni, M., Yitzhaki, I., Kozol, R., Zilberberg, A., & Efroni, S. (2014). Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. Breast Cancer Research, 16, 464. doi: 10.1186/s13058-014-0464-0
   PubMed Web of Science ®Google Scholar
• DeLano, W. (2002). The {PyMOL} molecular graphics system. http://Pymol.Org. Retrieved from http://ci.nii.ac.jp/naid/10026107904/
   Google Scholar
• Duffy, M. J., Synnott, N. C., & Crown, J. (2017). Mutant p53 as a target for cancer treatment. European Journal of Cancer, 83, 258–265. doi: 10.1016/j.ejca.2017.06.023
   PubMed Web of Science ®Google Scholar
• Ferlay, J., Soerjomataram, I. I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., … Bray, F. (2012). Cancer incidence and mortality worldwide : Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), 359–386. doi: 10.1002/ijc.29210
   Google Scholar
• Franco-Gonzalez, J. F., Cruz, V., Ramos, J., & Martinez-Salazar, J. (2014). Protein-protein and protein-membrane interactions regarding the erbb2/trastuzumab-fab complexes. A coarse-grained molecular dynamics description. Biophysical Journal, 106(2), 666a–667a. doi: 10.1016/j.bpj.2013.11.3690
   Web of Science ®Google Scholar
• Fukuyoshi, S., Kometani, M., Watanabe, Y., Hiratsuka, M., Yamaotsu, N., Hirono, S., … Oda, A. (2016). Molecular dynamics simulations to investigate the influences of amino acid mutations on protein three-dimensional structures of cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62. PLoS One, 11(4), e0152946. doi: 10.1371/journal.pone.0152946
   PubMed Web of Science ®Google Scholar
• Ganesan, P., Janku, F., Naing, A., Hong, D. S., Tsimberidou, A. M., Falchook, G. S., … Kurzrock, R. (2013). Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Molecular Cancer Therapeutics, 12(12), 2857–2863. doi: 10.1158/1535-7163.MCT-13-0319-T
   PubMed Web of Science ®Google Scholar
• Gatzka, M. V. (2018). Targeted tumor therapy remixed—an update on the use of small-molecule drugs in combination therapies. Cancers, 10, pii: E155. doi: 10.3390/cancers10060155
   Web of Science ®Google Scholar
• Gaynor, K. U., Grigorieva, I. V., Allen, M. D., Esapa, C. T., Head, R. A., Gopinath, P., … Thakker, R. V. (2013). GATA3 Mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness. Hormones and Cancer, 4, 123–139. doi: 10.1007/s12672-013-0138-x
   PubMed Web of Science ®Google Scholar
• Georgescu, C., Longabaugh, W. J. R., Scripture-Adams, D. D., David-Fung, E.-S., Yui, M. A., Zarnegar, M. A., … Rothenberg, E. V. (2008). A gene regulatory network armature for T lymphocyte specification. Proceedings of the National Academy of Sciences of the United States of America, 105, 20100–20105. doi: 10.1073/pnas.0806501105
   PubMed Web of Science ®Google Scholar
• Godwin, R. C., Gmeiner, W. H., & Salsbury, F. R. (2018). All-atom molecular dynamics comparison of disease-associated zinc fingers. Journal of Biomolecular Structure and Dynamics, 36, 2581–2594. doi: 10.1080/07391102.2017.1363662
   PubMed Web of Science ®Google Scholar
• Hermanto, S., Yusuf, M., Mutalib, A., & Hudiyono, S. (2017). Molecular dynamic simulation of Trastuzumab F(ab’)2structure in corporation with HER2 as a theranostic agent of breast cancer. IOP Conf. Series: Journal of Physics: Conference Series , 835, 012005. doi: 10.1088/1742-6596/835/1/012005
   Google Scholar
• Ho, I.-C., Vorhees, P., Marin, N., Oakley, B., Tsai, S.-F., Orkin, S., & Leiden, J. (1991). Human GATA-3: A lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. The EMBO Journal, 10(5), 1187–1192. doi: 10.1002/j.1460-2075.1991.tb08059.x
   PubMed Web of Science ®Google Scholar
• Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018). Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 15, 222–234. doi: 10.1038/nrurol.2018.9
   PubMed Web of Science ®Google Scholar
• Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., … Kurzrock, R. (2011). PIK3CA mutations in patients with advanced cancers treated with pi3k/akt/mtor axis inhibitors. Molecular Cancer Therapeutics, 10(3), 558–565. doi: 10.1158/1535-7163.MCT-10-0994
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Maxwell, D. S., & Tirado-Rives, J. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society, 118, 11225–11236. doi: 10.1021/ja9621760
   Web of Science ®Google Scholar
• Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., … Ding, L. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471), 333–339. doi: 10.1038/nature12634
   PubMed Web of Science ®Google Scholar
• Karnati, K. R., & Wang, Y. (2018). Understanding the co-loading and releasing of doxorubicin and paclitaxel using chitosan functionalized single-walled carbon nanotubes by molecular dynamics simulations. Physical Chemistry Chemical Physics, 20(14), 9389–9400. doi: 10.1039/C8CP00124C
   PubMed Web of Science ®Google Scholar
• Kato, K., Nakayoshi, T., Fukuyoshi, S., Kurimoto, E., & Oda, A. (2017). Validation of molecular dynamics simulations for prediction of three-dimensional structures of small proteins. Molecules, 22(10), pii: E1716. doi: 10.3390/molecules22101716
   Web of Science ®Google Scholar
• Khadka, N. K., Cheng, X., Ho, C. S., Katsaras, J., & Pan, J. (2015). Interactions of the anticancer drug tamoxifen with lipid membranes. Biophysical Journal, 108(10), 2492–2501. doi: 10.1016/j.bpj.2015.04.010
   PubMed Web of Science ®Google Scholar
• Khandekar, M. J., Piotrowska, Z., Willers, H., & Sequist, L. V. (2018). Role of epidermal growth factor receptor (EGFR) inhibitors and radiation in the management of brain metastases from EGFR mutant lung cancers. The Oncologist, 23, 1054–1062. doi: 10.1634/theoncologist.2017-0557
   PubMed Web of Science ®Google Scholar
• Kong, S. L., Li, G., Loh, S. L., Sung, W. K., & Liu, E. T. (2011). Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Molecular Systems Biology, 7, 526. doi: 10.1038/msb.2011.59
   PubMed Web of Science ®Google Scholar
• Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D., & Werb, Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127(5), 1041–1055. doi: 10.1016/j.cell.2006.09.048
   PubMed Web of Science ®Google Scholar
• Liao, B.-C., Bai, Y.-Y., Lee, J.-H., Lin, C.-C., Lin, S.-Y., Lee, Y.-F., … Yang, P.-C. (2018). Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association, 117(4), 326–331. doi: 10.1016/j.jfma.2017.04.018
   PubMed Web of Science ®Google Scholar
• Liu, J., Prager–van der Smissen, W. J. C., Look, M. P., Sieuwerts, A. M., Smid, M., Meijer–van Gelder, M. E., … Martens, J. W. M. (2016). GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Letters, 376(1), 104–109. doi: 10.1016/j.canlet.2016.03.038
   PubMed Web of Science ®Google Scholar
• Lu, H. Y., Qin, J., Han, N., Lei, L., Xie, F., & Li, C. (2018). EGFR, KRAS, BRAF, PTEN, AND PIK3CA mutation in plasma of small cell lung cancer patients. OncoTargets and Therapy, 11, 2217–2226. doi: 10.2147/OTT.S159612
   PubMed Web of Science ®Google Scholar
• MacKerell, A. D., & Nilsson, L. (2008). Molecular dynamics simulations of nucleic acid-protein complexes. Current Opinion in Structural Biology, 18, 194–199. doi: 10.1016/j.sbi.2007.12.012
   PubMed Web of Science ®Google Scholar
• McGee, T. D., Edwards, J., & Roitberg, A. E. (2008). Preliminary molecular dynamic simulations of the estrogen receptor alpha ligand binding domain from antagonist to apo. International Journal of Environmental Research and Public Health, 5(2), 111–114. doi: 10.3390/ijerph5020111
   PubMedGoogle Scholar
• Mehra, R., Varambally, S., Ding, L., Shen, R., Sabel, M. S., Ghosh, D., … Kleer, C. G. (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Research, 65(24), 11259–11264. doi: 10.1158/0008-5472.CAN-05-2495
   PubMed Web of Science ®Google Scholar
• Merika, M., & Orkin, S. H. (1993). DNA-binding specificity of GATA family transcription factors. Molecular and Cellular Biology, 13, 3999–4010. doi: 10.1128/MCB.13.7.3999
   PubMed Web of Science ®Google Scholar
• Natarajan, K., & Senapati, S. (2012). Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations. PLoS One, 7(8), e42351. doi: 10.1371/journal.pone.0042351
   PubMed Web of Science ®Google Scholar
• Olivier, M., Hollstein, M., & Hainaut, P. (2010). TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology, 2, a001008. doi: 10.1101/cshperspect.a001008
   PubMed Web of Science ®Google Scholar
• Pereira, B., Chin, S. F., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., … Caldas, C. (2016). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature Communications, 7, 11479. doi: 10.1038/ncomms11479
   PubMed Web of Science ®Google Scholar
• Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., … Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752. doi: 10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Pierce, B. G., Wiehe, K., Hwang, H., Kim, B. H., Vreven, T., & Weng, Z. (2014). ZDOCK server: Interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics, 30(12), 1771–1773. doi: 10.1093/bioinformatics/btu097
   PubMed Web of Science ®Google Scholar
• Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018). KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Molecular Cancer, 17, 33. doi: 10.1186/s12943-018-0789-x
   PubMed Web of Science ®Google Scholar
• Sagendorf, J. M., Berman, H. M., & Rohs, R. (2017). DNAproDB: An interactive tool for structural analysis of DNA-protein complexes. Nucleic Acids Research, 45, W89–W97. doi: 10.1093/nar/gkx272
   PubMed Web of Science ®Google Scholar
• Schwaigerlehner, L., Pechlaner, M., Mayrhofer, P., Oostenbrink, C., & Kunert, R. (2018). Lessons learned from merging wet lab experiments with molecular simulation to improve mAb humanization. Protein Engineering, Design and Selection, 31, 257–265. doi: 10.1093/protein/gzy009
   PubMed Web of Science ®Google Scholar
• Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., … Borresen-Dale, A.-L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences, 98(19), 10869–10874. doi: 10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Sridharan, U., Ragunathan, P., Spellerberg, B., & Ponnuraj, K. (2019). Molecular dynamics simulation of metal free structure of Lmb, a laminin-binding adhesin of Streptococcus agalactiae: Metal removal and its structural implications. Journal of Biomolecular Structure and Dynamics, 37, 714–725. doi: 10.1080/07391102.2018.1438923
   PubMed Web of Science ®Google Scholar
• Sun, T. Y., Wang, Q., Zhang, J., Wu, T., & Zhang, F. (2013). Trastuzumab-Peptide interactions: Mechanism and application in structure-based ligand design. International Journal of Molecular Sciences, 14(8), 16836–16850. doi: 10.3390/ijms140816836
   PubMed Web of Science ®Google Scholar
• Takaku, M., Grimm, S. A., Roberts, J. D., Chrysovergis, K., Bennett, B. D., Myers, P., … Wade, P. A. (2018). GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nature Communications, 9(1), 1059. doi: 10.1038/s41467-018-03478-4
   PubMedGoogle Scholar
• Takaku, M., Grimm, S. A., Shimbo, T., Perera, L., Menafra, R., Stunnenberg, H. G., … Wade, P. A. (2016). GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler. Genome Biology, 17(1), 36. doi: 10.1186/s13059-016-0897-0
   PubMedGoogle Scholar
• Takaku, M., Grimm, S. A., & Wade, P. A. (2015). GATA3 in breast cancer: Tumor suppressor or oncogene? Gene Expression, 16(4), 163. doi: 10.3727/105221615X14399878166113
   PubMed Web of Science ®Google Scholar
• Tan, H., Bao, J., & Zhou, X. (2015). Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Scientific Reports, 5, 12566. doi: 10.1080/00222939100770081
   PubMed Web of Science ®Google Scholar
• Theodorou, V., Stark, R., Menon, S., & Carroll, J. S. (2013). GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Research, 23(1), 12–22. doi: 10.1101/gr.139469.112
   PubMed Web of Science ®Google Scholar
• Tindemans, I., Serafini, N., DiSanto, J. P., & Hendriks, R. W. (2014). GATA-3 function in innate and adaptive immunity. Immunity, 41, 191–206. doi: 10.1016/j.immuni.2014.06.006
   PubMed Web of Science ®Google Scholar
• Trainor, C. D., Omichinski, J. G., Vandergon, T. L., Gronenborn, A. M., Clore, G. M., & Felsenfeld, G. (1996). A palindromic regulatory site within vertebrate GATA-1 promoters requires both zinc fingers of the GATA-1 DNA-binding domain for high-affinity interaction. Molecular and Cellular Biology, 16, 2238–2247. doi: 10.1128/MCB.16.5.2238
   PubMed Web of Science ®Google Scholar
• Tripathi, S., Srivastava, G., & Sharma, A. (2016). Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells. Biochemical and Biophysical Research Communications, 476(4), 273–279. doi: 10.1016/j.bbrc.2016.05.112
   PubMed Web of Science ®Google Scholar
• Usary, J., Llaca, V., Karaca, G., Presswala, S., Karaca, M., He, X., … Perou, C. M. (2004). Mutation of GATA3 in human breast tumors. Oncogene, 23, 7669–7678. doi: 10.1038/sj.onc.1207966
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005). Gromacs; fast, flexible and free. Journal of Computational Chemistry, 26(16), 1701–1718. doi: 10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Wang, X. Y., Zhang, L., Wei, X. H., & Wang, Q. (2013). Molecular dynamics of paclitaxel encapsulated by salicylic acid-grafted chitosan oligosaccharide aggregates. Biomaterials, 34(7), 1843–1851. doi: 10.1016/j.biomaterials.2012.11.024
   PubMed Web of Science ®Google Scholar
• Yu, M., Riva, L., Xie, H., Schindler, Y., Moran, T. B., Cheng, Y., … Cantor, A. B. (2009). Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Molecular Cell, 36, 682–695. doi: 10.1016/j.molcel.2009.11.002
   PubMed Web of Science ®Google Scholar
• Zhang, L. F., Zheng, Q. C., & Zhang, H. X. (2019). Recognition mechanism of Wilms’ tumour suppressor protein and DNA triplets: Insights from molecular dynamics simulation and free energy analysis. Journal of Biomolecular Structure and Dynamics, 37, 562–575. doi: 10.1080/07391102.2018.1433066
   PubMed Web of Science ®Google Scholar